224 related articles for article (PubMed ID: 30018044)
1. Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma.
Lewin J; Davidson S; Anderson ND; Lau BY; Kelly J; Tabori U; Salah S; Butler MO; Aung KL; Shlien A; Dickson BC; Abdul Razak AR
Cancer Immunol Res; 2018 Sep; 6(9):1001-1007. PubMed ID: 30018044
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond.
Brahmi M; Vanacker H; Dufresne A
Curr Opin Oncol; 2020 Jul; 32(4):295-300. PubMed ID: 32541316
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.
Paoluzzi L; Maki RG
JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Histogenesis and Diagnostic Strategy Using Immunoassay and RT-PCR in Alveolar Soft Part Sarcoma.
Ju X; Sun K; Liu R; Li S; Abulajiang G; Zou H; Lan J; Ren Y; Jiang J; Liang W; Pang L; Li F
Pathol Oncol Res; 2018 Jul; 24(3):593-600. PubMed ID: 28766250
[TBL] [Abstract][Full Text] [Related]
6. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
Argani P; Antonescu CR; Illei PB; Lui MY; Timmons CF; Newbury R; Reuter VE; Garvin AJ; Perez-Atayde AR; Fletcher JA; Beckwith JB; Bridge JA; Ladanyi M
Am J Pathol; 2001 Jul; 159(1):179-92. PubMed ID: 11438465
[TBL] [Abstract][Full Text] [Related]
7. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.
Groisberg R; Roszik J; Conley AP; Lazar AJ; Portal DE; Hong DS; Naing A; Herzog CE; Somaiah N; Zarzour MA; Patel S; Brown RE; Subbiah V
Mol Cancer Ther; 2020 May; 19(5):1165-1172. PubMed ID: 32127467
[TBL] [Abstract][Full Text] [Related]
8. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.
Yang Y; Beeraka NM; Liu J; Zuo X; Wang X; Li T; Fan R
Curr Pharm Des; 2022; 28(41):3404-3412. PubMed ID: 36154597
[TBL] [Abstract][Full Text] [Related]
9. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.
Ladanyi M; Lui MY; Antonescu CR; Krause-Boehm A; Meindl A; Argani P; Healey JH; Ueda T; Yoshikawa H; Meloni-Ehrig A; Sorensen PH; Mertens F; Mandahl N; van den Berghe H; Sciot R; Dal Cin P; Bridge J
Oncogene; 2001 Jan; 20(1):48-57. PubMed ID: 11244503
[TBL] [Abstract][Full Text] [Related]
10. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
Xie L; Liang X; Xu J; Sun X; Liu K; Sun K; Li Y; Tang X; Li X; Zhan X; Niu X; Guo W
BMC Cancer; 2023 Sep; 23(1):868. PubMed ID: 37715133
[TBL] [Abstract][Full Text] [Related]
11. [Detection of ASPL-TFE3 fusion gene by reverse transcriptase polymerase chain reaction in paraffin-embedded tumor tissues of alveolar soft part sarcoma].
Pang LJ; Li F; Chang B; Hu WH; Lu TC; Li XX; Li HA; Jiang JF
Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):508-12. PubMed ID: 15634444
[TBL] [Abstract][Full Text] [Related]
12. Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues.
Pang LJ; Chang B; Zou H; Qi Y; Jiang JF; Li HA; Hu WH; Chen YZ; Liu CX; Zhang WJ; Li F
Diagn Mol Pathol; 2008 Dec; 17(4):245-52. PubMed ID: 18382356
[TBL] [Abstract][Full Text] [Related]
13. A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma.
Mariuk-Jarema A; Koseła-Paterczyk H; Rogala P; Klimczak A; Wągrodzki M; Maksymiuk B; Rutkowski P
Tumori; 2020 Dec; 106(6):NP9-NP13. PubMed ID: 32567515
[TBL] [Abstract][Full Text] [Related]
14. Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial.
Lee CJ; Modave E; Boeckx B; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Debiec-Rychter M; Sciot R; Lambrechts D; Wozniak A; Schöffski P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628499
[TBL] [Abstract][Full Text] [Related]
15. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
Schöffski P; Wozniak A; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Gelderblom H; Italiano A; Lindner LH; Hennig I; Strauss S; Zakotnik B; Anthoney A; Albiges L; Blay JY; Reichardt P; Sufliarsky J; van der Graaf WTA; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Raveloarivahy T; Collette S; Stacchiotti S
Ann Oncol; 2018 Mar; 29(3):758-765. PubMed ID: 29216400
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.
Hindi N; Razak A; Rosenbaum E; Jonczak E; Hamacher R; Rutkowski P; Bhadri VA; Skryd A; Brahmi M; Alshibany A; Jagodzinska-Mucha P; Bauer S; Connolly E; Gelderblom H; Boye K; Henon C; Bae S; Bogefors K; Vincenzi B; Martinez-Trufero J; Lopez-Martin JA; Redondo A; Valverde C; Blay JY; Moura DS; Gutierrez A; Tap W; Martin-Broto J
ESMO Open; 2023 Dec; 8(6):102045. PubMed ID: 38016251
[TBL] [Abstract][Full Text] [Related]
17. Alveolar soft part sarcoma of lung: report of a unique case with emphasis on diagnostic utility of molecular genetic analysis for TFE3 gene rearrangement and immunohistochemistry for TFE3 antigen expression.
Zhao M; Rao Q; Wu C; Zhao Z; He X; Ru G
Diagn Pathol; 2015 Sep; 10():160. PubMed ID: 26369552
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.
Groisberg R; Hong DS; Behrang A; Hess K; Janku F; Piha-Paul S; Naing A; Fu S; Benjamin R; Patel S; Somaiah N; Conley A; Meric-Bernstam F; Subbiah V
J Immunother Cancer; 2017 Dec; 5(1):100. PubMed ID: 29254498
[TBL] [Abstract][Full Text] [Related]
19. Advances in the management of alveolar soft part sarcoma.
O'Sullivan Coyne G; Naqash AR; Sankaran H; Chen AP
Curr Probl Cancer; 2021 Aug; 45(4):100775. PubMed ID: 34284873
[TBL] [Abstract][Full Text] [Related]
20. Alveolar Soft Part Sarcoma of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases With Emphasis on its Distinction From Morphologic Mimics.
Schoolmeester JK; Carlson J; Keeney GL; Fritchie KJ; Oliva E; Young RH; Nucci MR
Am J Surg Pathol; 2017 May; 41(5):622-632. PubMed ID: 28009610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
